Film-Coated Tablet | Antiprotozoal & Nitroimidazole Antibacterial
Each film-coated tablet contains: Tinidazole BP 500 mg; excipients q.s.
Usage: Treatment of susceptible protozoal infections and certain anaerobic bacterial conditions, as approved locally.
Therapeutic category: Antiprotozoal / Antibacterial (Nitroimidazole).
SKU: Tinidazole Tablets BP 500 mg
Categories: Pharmaceutical Exporter India · Pharmaceutical Formulations India · WHO GMP Certified Formulations
Tinidazole Tablets BP is listed for pharmaceutical business-to-business enquiries. Exact active ingredients, formulation, strength, pack configuration and manufacturer details should be confirmed against the product label and approved technical documentation before ordering.
Tinidazole is a nitroimidazole antimicrobial active against susceptible protozoa and certain anaerobic bacteria. The supplied product label identifies a Tinidazole BP 500 mg film-coated tablet. It may be prescribed for giardiasis, amoebiasis, trichomoniasis or bacterial vaginosis where approved. Treatment selection depends on diagnosis, patient factors and local guidelines.
The supplied company information identifies Healthy Life Pharma Pvt. Ltd. as manufacturer and Healthy Inc as exporter. WHO-GMP status, manufacturing location, certifications and market authorizations require documentary verification.
| Product name | Tinidazole Tablets |
|---|---|
| Active ingredient | Tinidazole BP 500 mg per film-coated tablet |
| Confirmed strength | 500 mg |
| Dosage form | Film-coated oral tablet |
| Pharmacopoeial reference | BP (per supplied label) |
| CAS number | 19387-91-8 |
| Therapeutic class | Antiprotozoal / Nitroimidazole antibacterial |
| Other strengths | 300 mg and 1000 mg mentioned in background only; not confirmed for this SKU |
| Packaging / shelf life | To be confirmed against registered product and stability data |
Film-coated tinidazole tablet production generally requires controlled raw-material identification, blending, granulation or direct compression as validated, tablet compression and coating. Film coating may improve swallowability and help mask bitter taste. Specific excipients, coating brand, tooling, granulation method and packaging configuration should not be asserted without the approved master formula and batch documentation.
Quality testing should follow the applicable approved BP monograph and registered specification, including identity, assay, dosage-unit uniformity, dissolution, related substances, packaging integrity and stability as applicable. Exact assay or dissolution acceptance limits cannot be established from the supplied label alone; they must be taken from the approved specification and validated methods.
Within susceptible organisms, tinidazole undergoes reductive activation and forms compounds that damage microbial DNA. Approved uses can include giardiasis, intestinal or extraintestinal amoebiasis, trichomoniasis and bacterial vaginosis, depending on the country and product authorization. It is not a general treatment for all worms (helminths), viral infections or routine bacterial infections. Partner management and STI testing may be necessary for trichomoniasis.
For B2B enquiries, confirm the current manufacturing license, GMP documentation, product registration status, certificate of analysis, stability dossier, packaging specifications and country-specific labeling. CTD/ACTD, COPP and FSC availability must be verified for the destination market. Export supply is subject to local antimicrobial and import regulations.
Q: Which product strength is confirmed?
A: Tinidazole BP 500 mg in each film-coated tablet.
Q: Is tinidazole the same as metronidazole?
A: No. Both are nitroimidazoles, but dosing, pharmacokinetics and approved uses differ; neither should be substituted without clinical advice.
Q: Can alcohol be consumed during treatment?
A: Avoid alcohol and products containing ethanol or propylene glycol during treatment and for 3 days after the final dose, in line with product labeling.
Q: Is a 1000 mg tablet confirmed?
A: No. Only 500 mg is supported by the supplied primary composition.
Dosage varies substantially by indication, age, weight, pregnancy status and local approved labeling. Certain conditions may be treated with a single prescribed dose, while others require multiple days of treatment. 500 mg describes tablet strength, not a universal treatment dose. Tinidazole is commonly taken with food to reduce gastrointestinal discomfort. Use only on prescription and complete the prescribed course; do not self-treat suspected sexually transmitted infections.
Possible effects include nausea, metallic or bitter taste, abdominal discomfort, headache and dizziness. Rare serious effects include peripheral neuropathy, seizures and hypersensitivity. Stop the medicine and seek medical advice for new numbness, unsteadiness, seizures or severe rash. Review interactions, including warfarin and certain other medicines. Avoid alcohol and propylene glycol during treatment and for 72 hours afterward. Pregnancy and breastfeeding restrictions depend on indication and local labeling; tinidazole is generally avoided in the first trimester, and breastfeeding interruption for 72 hours after the last dose may be recommended. A clinician should assess risks and alternatives.
Keep in the original packaging, protected from excess moisture and light, and out of reach of children. Follow the storage temperature and expiry date on the approved product label; a specific 36-month shelf life or below-30°C requirement is not verified by the supplied composition.
For healthcare professional and B2B reference. Product availability, approvals, certifications, manufacturing processes, packaging and prescribing details must be verified for the relevant market.